Lacy Wilson
Family · Lancaster, OHNPI 1568111482
Payments from drug & device makers
Across 132 payments — averaging $15.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$384
- Novo Nordisk$308
- Sumitomo Pharma America, Inc.$160
- Bayer$133
- Otsuka America Pharmaceutical, Inc.$121
- Lilly USA, LLC$115
- plus $868 from 24 others
What the payments were for
- Food & beverage$2,05899%
- Other$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 30 | $384 |
| Novo Nordisk | 20 | $308 |
| Sumitomo Pharma America, Inc. | 8 | $160 |
| Bayer | 7 | $133 |
| Otsuka America Pharmaceutical, Inc. | 7 | $121 |
| Lilly USA, LLC | 7 | $115 |
| Pfizer | 7 | $108 |
| IBSA Pharma Inc. | 6 | $91 |
| AstraZeneca | 5 | $76 |
| Amgen | 4 | $65 |
| Dexcom, Inc. | 3 | $55 |
| Astellas Pharma US Inc | 3 | $52 |
| Indivior Inc. | 2 | $42 |
| Exact Sciences | 2 | $39 |
| Bausch Health US, LLC | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| Abbott | 1 | $30 |
| Lucid Diagnostics Inc. | 2 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Novartis | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $19 |
| GSK | 1 | $17 |
| Evoke Pharma, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Merck | 1 | $16 |
| Johnson & Johnson | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
| Urovant Sciences Inc | 1 | $12 |
How this compares
$2,088 in reported general payments places this provider in the 80th percentile of 6,812 family providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 14 | $16,795 |
| Duloxetine Hcl | 14 | $865 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 38 | $857 |
| Atorvastatin Calcium | 50 | $743 |
| Omeprazole | 36 | $640 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 73 | $503 |
| Losartan Potassium | 36 | $478 |
| Montelukast Sodium | 22 | $443 |
| Rosuvastatin Calcium | 11 | $409 |
| Doxycycline Monohydrate | 22 | $381 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 35 | $380 |
| Gabapentin | 24 | $347 |
| Bupropion XlBupropion Hcl | 12 | $321 |
| Metoprolol Succinate | 17 | $289 |
| Fluticasone Propionate | 19 | $259 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $308 | $16,79514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,812 family providers in Ohio.
Other family in Lancaster
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.